Join Dr. Ethan as he delves into the science of Retatrutide, a groundbreaking synthetic peptide developed by Eli Lilly.

This episode unpacks how Retatrutide targets three key hormone receptors—GLP-1, GIP, and glucagon—revolutionizing approaches to weight management, glucose regulation, and metabolic health. Explore the molecular biology, receptor targets, and clinical trial results that set Retatrutide apart from drugs like Semaglutide (Ozempic) and Tirzepatide (Mounjaro). Whether you’re a clinician, student, or just curious about the future of obesity and diabetes treatment, this accessible overview illuminates the intersection of chemistry, biology, and innovative drug design. Like and share this video if you want to stay updated on leading-edge metabolic research!

#Retatrutide #MetabolicHealth #ObesityTreatment #Diabetes #MolecularBiology #WeightLoss #MedicalInnovation